---
title: "Sana Biotechnology, Inc. Updates on Key Programs at J.P. Morgan Conference"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272589643.md"
description: "Sana Biotechnology, Inc. provided key updates on its therapeutic programs at the J.P. Morgan Healthcare Conference on January 14, 2026. Highlights include the UP421 therapy demonstrating 12-month survival without immunosuppression, an expected IND filing and Phase 1 trial for SC451 this year, and the SG293 CAR T cell therapy aiming for initial human data in 2026. The company also discussed advancements in hypoimmune technology for type 1 diabetes and its potential impact on blood cancers and autoimmune diseases."
datetime: "2026-01-14T17:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272589643.md)
  - [en](https://longbridge.com/en/news/272589643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272589643.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/272589643.md) | [繁體中文](https://longbridge.com/zh-HK/news/272589643.md)


# Sana Biotechnology, Inc. Updates on Key Programs at J.P. Morgan Conference

**On January 14, 2026, Sana Biotechnology, Inc. presented significant updates on its therapeutic programs at the J.P. Morgan Healthcare Conference.**

**Key Highlights:**

-   UP421 therapy shows 12-month survival and function without immunosuppression.
-   SC451 IND filing and Phase 1 trial expected to start this year.
-   SG293 CAR T cell therapy aims for initial human data in 2026.
-   Advancements in hypoimmune technology for type 1 diabetes treatment.
-   Potential transformative impact on blood cancers and autoimmune diseases.

Original SEC Filing: Sana Biotechnology, Inc. \[ SANA \] - 8-K - Jan. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相关股票

- [Sana Biotechnology (SANA.US)](https://longbridge.com/zh-CN/quote/SANA.US.md)

## 相关资讯与研究

- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-CN/news/281035304.md)
- [Sana Biotechnology’s Strategic Focus on T1D Therapies Justifies Buy Rating](https://longbridge.com/zh-CN/news/264847672.md)
- [AstraZeneca's Combo Therapy Shows Improved Progression-free Survival in Late-stage Liver Cancer Trial](https://longbridge.com/zh-CN/news/281477081.md)
- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/zh-CN/news/281090118.md)
- [ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH](https://longbridge.com/zh-CN/news/281541014.md)